ArticleScientific reports2024
Green synthesis of copper oxide nanoparticles using walnut shell and their size dependent anticancer effects on breast and colorectal cancer cell lines.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Green Fabrication and Characterization of Copper Oxide Nanoparticles Using C. Gigantea Leaf Extract and Their ROS-Mediated Anticancer Activity Against A549 Lung Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Copper/Copper Oxide Nanoparticles: Biological Synthesis, Characterization and Potential Biomedical Applications: Advances and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Advancements in Inorganic Chiral Nanomaterials for Anti-Tumor Immunotherapy.Cancer science · 2026Review
- Efficacy of Phallusia arabica mediated tenorite nanoparticles in growth inhibition of clinical pathogens and A549 human lung cancer cells.Scientific reports · 2026Article
- Biosynthesis of zinc oxide nanoparticles and evaluation of anticancer activity against MCF-7 breast cancer cell line via phyto-synthesised nanoparticles.Scientific reports · 2026Article
- A Comprehensive Review on Copper Oxide Nanoparticles: Physicochemical Parameters, Pharmacological Potential and Pathophysiological Effects.International journal of nanomedicine · 2026Review
- Investigations of Cu2ONPs - Orange Peels: Biosynthesis, Characterization, and Anticancer Activity on a Cytotoxic Breast Cancer Cell Line.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Copper Nanoparticles Synthesized by Chemical Reduction with Medical Applications.International journal of molecular sciences · 2025Article
- Biogenic gold nanoparticles synthesized fromOpen life sciences · 2025Article
- Tailoring CdO-CuO-ZnO Mixed Metal Oxide Nanocomposites for Anticancer Activity via Co-Precipitation Method.Nanotechnology, science and applications · 2025Article
- Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal oxide nanoparticles(NPs) contain unique properties which have made them attractive agents in cancer treatment. The CuO nanoparticles were green synthesized using walnut shell powder in different calcination temperatures (400°, 500°, 700°, and 900 °C). The CuO nanoparticles are characterized by FTIR, XRD, BET, SEM and DLS analyses. SEM and DLS analyses showed that by increasing the required calcination temperature for synthesizing the NPs, their size was increased. DPPH analysis displayed no significant anti-oxidative properties of the CuO NPs. The MTT analysis showed that all synthesized CuO NPs exhibited cytotoxic effects on MCF-7, HCT-116, and HEK-293 cell lines. Among the CuO NPs, the CuO-900 NPs showed the least cytotoxic effect on the HEK-293 cell line (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.